0001638599-19-000935.txt : 20191105 0001638599-19-000935.hdr.sgml : 20191105 20191105124044 ACCESSION NUMBER: 0001638599-19-000935 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191029 FILED AS OF DATE: 20191105 DATE AS OF CHANGE: 20191105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Isett Thomas Francis 3rd CENTRAL INDEX KEY: 0001773100 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 191192471 MAIL ADDRESS: STREET 1: C/O IBIO INC. 600 MADISON AVENUE STREET 2: SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 4 1 doc4_6338.xml PRIMARY DOCUMENT X0306 4 2019-10-29 0 0001420720 iBio, Inc. IBIO 0001773100 Isett Thomas Francis 3rd C/O IBIO, INC. 600 MADISON AVENUE SUITE 1601 NEW YORK NY 10022 1 0 0 0 Series C Convertible Preferred Stock 0.20 2019-10-29 4 P 0 20 1000 A Common Stock 100000 350000 D Series A Warrants (Right to Buy) 0.22 2019-10-29 4 P 0 100000 1000 A 2019-10-29 2021-10-29 Common Stock 100000 350000 D Series B Warrants (Right to Buy) 0.22 2019-10-29 4 P 0 100000 1000 A 2019-10-29 2026-10-29 Common Stock 100000 350000 D The shares of Series C Convertible Preferred Stock, $0.001 par value (the "Series C Preferred Shares"), were acquired by Mr. Isett in a public offering by iBio, Inc. ("iBio"). Each Series C Preferred Share has a stated value of $1,000 and is convertible into shares of iBio's common stock at any time and from time to time at the option of the holder at a price of $0.20 per share, subject to adjustment as provided in the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock, provided that the Series C Preferred Shares may not be converted if the holder, together with the holder's affiliates, would beneficially own over 4.99% (which may be increased up to 9.99% upon election by the holder on 61 days' notice) of iBio's outstanding common stock at the time of conversion. The Series C Preferred Shares have no expiration date. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000. Reflects number of securities beneficially owned following all transactions reported on this Form 4, on an as converted to common stock basis. The Series A Warrants were acquired by Mr. Isett in a public offering by iBio. The Series A Warrants were sold together with Series C Preferred Shares and Series B Warrants in the public offering. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000. The Series B Warrants were acquired by Mr. Isett in a public offering by iBio. The Series B Warrants were sold together with Series C Preferred Shares and Series A Warrants in the public offering. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000. /s/Thomas Isett 2019-11-05